Ontsteking heeft een slechte reputatie die slechts deels terecht is. De acute vorm is een van de nuttigste dingen die je lichaam doet: de roodheid, warmte en zwelling rond een wond of infectie zijn het immuunsysteem dat ter plaatse komt om de dreiging te elimineren en herstel te starten, waarna het verdwijnt.
Het probleem is de andere soort, een laaggradige ontstekingsstoornis die jarenlang aanhoudt met leeftijd en lichaamsvet, en die verband houdt met hartaandoeningen, type 2-diabetes, kanker en meer. Deze pagina legt het verschil uit, wat daadwerkelijk de chronische vorm verlaagt, en waarom veel van wat als ontstekingsremmend wordt verkocht op zeer weinig steun berust.
Findings & Outcomes
Inflammation sits underneath a large number of conditions and everyday practices, so understanding it once makes the rest clearer. Exercise, sleep, body fat and diet keep showing up as levers, and the blood marker CRP appears on many lab reports. All of them trace back to the same biology.
What Acute Inflammation Does
Acute inflammation is the immune system's first response to injury and infection, and it is useful. Damaged or infected tissue releases signals, nearby blood vessels widen and turn leaky, and immune cells move into the area. That produces the warmth, swelling and soreness around a fresh cut, a sprain or a sore throat. The response clears the threat, sets up repair, then switches off.
Switching off is itself an active process, run by its own resolving signals. Acute inflammation is a defense the body needs; one that could not mount it would be in serious trouble.
When It Does Not Switch Off
The trouble begins when a low level of that same signaling never fully resolves, persisting for years. This is chronic low-grade inflammation, and it shows none of the visible redness or heat of the acute kind. It surfaces instead as a modest, persistent rise in inflammatory signals in the blood, measured most often as CRP (C-reactive protein) and IL-6 (interleukin-6).
Two forces feed it more than any others.
- Age. Across a lifetime the body settles into a chronically raised inflammatory state, a pattern named inflammaging. It is driven by worn-out cells that accumulate and leak inflammatory signals, by changes in the gut, and by years of low-level immune activity. In older adults, a higher IL-6 is among the more consistent blood predictors of frailty, disability and earlier death.
- Body fat, in particular the visceral fat around the organs. This is an active tissue that secretes inflammatory signals, so more visceral fat means more inflammatory signaling. Losing excess fat is one of the more reliable ways to bring the markers down.
Reviewing the evidence together, researchers find low-grade inflammation is one common thread through the top killers: heart disease, type 2 diabetes, several cancers, chronic kidney disease and neurodegeneration. How much of each disease it causes, and how much it merely accompanies, differs from one to the next. That difference is clearest for CRP, the marker most people can measure.
The Marker And The Mechanism
CRP is easy to measure, which is why it gets misunderstood. A raised CRP signals that the inflammatory state is active, and it does predict cardiovascular risk. It predicts risk; whether it causes the harm is a separate question. The cleanest evidence separating the two comes from genetics.
Mendelian randomization uses the gene variants people inherit at birth as a lifelong natural experiment. People who inherit variants that keep their CRP higher for life get no more coronary heart disease than anyone else. That points to CRP as a downstream readout of the inflammatory state: it tracks the process without driving it.
Run the same test one step upstream, on the IL-6 receptor, and the answer reverses: this pathway does cause harm. Variants that dampen IL-6 signaling go with lower coronary risk, so the IL-6 pathway is causal. The number on the lab report comes from a process that matters. Treating that process is what helps; pushing the CRP reading down for its own sake does nothing to it.
In the CANTOS trial, more than 10,000 people who had survived a heart attack, all still carrying a raised CRP, were given canakinumab. The drug is an antibody that blocks the inflammatory signal IL-1 beta, one step above IL-6.
It cut the rate of further cardiovascular events by about 15%, with no change in cholesterol. Inflammation itself is a causal, treatable driver of heart disease.
Canakinumab did not help people live longer overall, and it raised serious infections. That makes it a landmark proof that the pathway is causal, while its infection risk keeps it out of routine prevention.
What lowers it
Exercise is one of the better-supported levers. Regular training lowers CRP and IL-6 by a modest but measurable amount. A contracting muscle releases IL-6 into the blood as a signaling protein. From a working muscle, that IL-6 burst calms inflammation; the same molecule, sitting high in the blood day after day, does the opposite. That contrast is a case of hormesis: a brief, controlled stress that leaves the body better regulated. Training also trims the visceral fat that supplies the inflammatory signal in the first place.
Losing excess body fat lowers the same markers, for the same reason given above: the visceral fat is itself a source of the signaling. Diet quality is another lever, and it points at a larger driver. Much of that visceral fat is built by an ultra-processed food supply engineered around sugar, fat and salt. Such foods now provide roughly 58% of the calories in the average American adult's diet (NHANES). A Mediterranean pattern rich in olive oil lowers inflammatory markers compared with a low-fat control diet in trials, part of the wider case for whole foods.
Disturbed sleep, and both short and long sleep duration, go with higher CRP and IL-6 in observational studies. But short experiments that deprived healthy people of sleep did not raise these markers, so the link is observed without evidence that the sleep loss itself drives it. Not smoking matters too, since tobacco smoke is a direct and sustained inflammatory exposure.
None of these levers is dramatic on its own. And lowering CRP is only a sliver of why each one is good for you; they help mainly through other routes. The reliable ways to lower chronic inflammation are the same short, free habits that improve metabolic health broadly. They all come together in type 2 diabetes, where inflammation, body fat and metabolism act on each other. The practices that help there are resistance training and walking, alongside diet and sleep.
The Anti-Inflammatory Marketing Problem
Because inflammation matters, it has become one of the most stretched words in wellness marketing. Almost any food, supplement or device can be sold as anti-inflammatory, and the claim is hard to check because everyone already agrees inflammation is bad.
Most anti-inflammatory supplement claims rest on cell-culture studies, animal work, or small trials that track a blood marker instead of a disease. A compound that lowers a marker in a dish, or by a small amount in a short trial, has not been shown to prevent anything a person actually cares about.
The clear exception is a diagnosed inflammatory disease. In rheumatoid arthritis, inflammation is the pathology itself, drugs that block it directly are standard and effective care, and CRP there measures the very thing being treated. Inflammation becomes a target when it is a named disease. The everyday version is lowered by the ordinary levers.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Genetics show raising CRP does not itself cause heart disease
CRP is the number most people can measure, but the genetics say raising CRP does not itself cause heart disease, so it is a signal, not the culprit. The upstream IL-6 signal it reflects does look causal. Chasing the CRP number is not the same as changing the biology.
Mendelian randomization uses inherited genetic variants as a lifelong natural experiment. An individual-participant analysis of CRP gene variants across many cohorts found that genetically higher CRP was not associated with coronary heart disease, and a large genetic study reached the same conclusion, so CRP appears not to be causal. Applying the same method to the IL-6 receptor, variants that reduce IL-6 signaling were associated with lower coronary heart disease risk across 82 studies, consistent with IL-6 signaling being a causal driver upstream of CRP. Together they explain why CRP remains a useful risk marker while being the wrong thing to treat directly, and why the treatable target sits further up the pathway.
Who this may not transfer to:Pooled across many mixed-sex cohorts; the genetic findings are not sex-specific.
The studies · 4
C Reactive Protein Coronary Heart Disease Genetics Collaboration, Association between CRP and CHD: mendelian randomisation analysis based on individual participant data · BMJ 2011;342:d548
Elliott et al., Genetic loci associated with C-reactive protein levels and risk of coronary heart disease · JAMA 2009;302(1):37-48
IL6R Mendelian Randomisation Analysis Consortium, The interleukin-6 receptor as a target for prevention of coronary heart disease · Lancet 2012;379(9822):1214-1224
Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R Genetics Consortium), Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies · Lancet 2012;379(9822):1205-1213
Chronic inflammation contributes to heart disease, diabetes, cancer and neurodegeneration
The same defence response that heals a cut becomes a problem when it never fully switches off. Kept running at a low level for years, it is tied to heart disease, type 2 diabetes, cancer and more, and blood markers like CRP and IL-6 show it is happening.
This wide-ranging review synthesises the evidence that chronic low-grade inflammation is a common mechanistic thread across non-communicable disease. It describes how ageing, adiposity, physical inactivity, poor diet, disturbed sleep, smoking and chronic stress feed a persistent inflammatory state, and how that state is associated with, and mechanistically linked to, cardiovascular disease, type 2 diabetes, several cancers, chronic kidney disease, depression and neurodegeneration. It is a narrative synthesis, not a single trial, so it establishes the framework and the plausibility of causation, not proving that any one intervention against inflammation prevents any one disease.
Who this may not transfer to:A synthesis across mixed-sex human epidemiology spanning many diseases; not reported as sex-specific.
The study · 1
Furman et al., Chronic inflammation in the etiology of disease across the life span · Nat Med 2019;25(12):1822-1832
Inflammatory markers rise with age and track frailty and earlier death
As people get older, a slow background level of inflammation tends to build up. This pattern, called inflammaging, goes with more frailty and disability and a shorter life, and it is one reason IL-6 and CRP creep up with age.
These reviews describe inflammaging: an age-related rise in circulating proinflammatory markers, IL-6 and CRP prominent among them, driven by senescent cells that secrete inflammatory signals, expanding visceral adiposity, changes in the gut barrier and microbiome, and cumulative immune activation. In older-adult cohorts, elevated IL-6 in particular is among the more consistent blood predictors of frailty, loss of physical function and all-cause mortality. The reviews frame inflammaging as a contributor to biological ageing, not a proven single cause, and note it is partly modifiable through the same levers that lower inflammation at any age.
Who this may not transfer to:Reviews drawing on mixed-sex older-adult cohorts; not reported as sex-specific.
The studies · 2
Franceschi et al., Inflammaging: a new immune-metabolic viewpoint for age-related diseases · Nat Rev Endocrinol 2018;14(10):576-590
Franceschi & Campisi, Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases · J Gerontol A Biol Sci Med Sci 2014;69 Suppl 1:S4-9
Poor sleep and both short and long sleep go with higher CRP and IL-6
Poor or disrupted sleep, and sleeping too little or too much, all go with higher inflammation markers. This comes from observational studies; short experiments that deprived healthy people of sleep did not raise the markers, so it is an association rather than a proven cause. Sleep is one of the levers that tracks low-grade inflammation.
This systematic review and meta-analysis pooled 72 studies of sleep and inflammation. Sleep disturbance (poor quality, insomnia complaints) was associated with higher CRP and higher IL-6; long sleep duration was associated with higher CRP and IL-6; short sleep duration was associated with higher CRP. Experimental sleep deprivation and restriction were not associated with CRP, IL-6, or TNF-alpha, so this rests on observational associations rather than demonstrated causation. The associations are consistent but the effect sizes are moderate, the observational data cannot fully separate sleep from the conditions that disturb it, and both extremes of duration flagging suggests some of the long-sleep signal reflects underlying illness.
Who this may not transfer to:Pooled mixed-sex cohorts and experimental studies; not reported as sex-specific.
The study · 1
Irwin, Olmstead & Carroll, Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation · Biol Psychiatry 2016;80(1):40-52
Heart And Vascular
Blocking IL-1 beta cut major cardiac events about 15% with no change in cholesterol
In a large trial of heart-attack survivors, a drug that damps one inflammatory signal lowered the chance of another cardiac event by about 15%, without touching cholesterol. It did not help people live longer overall, and it slightly raised the risk of serious infections.
CANTOS randomized 10,061 patients with previous myocardial infarction and hsCRP of 2 mg/L or more to canakinumab (an anti-IL-1 beta monoclonal antibody) at 50, 150 or 300 mg every three months, or placebo. The 150 mg dose reduced the primary composite of non-fatal MI, non-fatal stroke and cardiovascular death (HR 0.85, 95% CI 0.74 to 0.98) over a median 3.7 years, an effect achieved with no change in lipids and driven by lowering inflammation. All-cause mortality was not significantly reduced, and canakinumab increased fatal infection and sepsis. About 25.7% of participants were women. It is the landmark proof of concept that inflammation is a causal, treatable target in atherosclerosis, and it is a single trial of an expensive drug that is not approved for this use.
Who this may not transfer to:About a quarter of participants were women; the trial was not powered to test whether the effect differs by sex.
This is evidence that inflammation itself drives heart disease, not a recommendation to take an anti-inflammatory drug for prevention. The infection risk and the absence of a survival benefit are why canakinumab is not used this way; the practical lever remains lowering inflammation through lifestyle.
The study · 1
Ridker et al. (CANTOS), Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease · N Engl J Med 2017;377(12):1119-1131
Immune Function
Regular exercise lowers CRP and IL-6 by a modest amount
Exercising regularly nudges inflammation down, by a modest but real amount. Part of it is that working muscle sends out its own anti-inflammatory signals, and part is that training trims the belly fat that keeps low-grade inflammation going.
A network meta-analysis of trials in middle-aged and older adults found that exercise training reduces systemic inflammatory markers including CRP and IL-6, with the clearest effects on the chronic resting level, not large swings. Mechanistically, contracting skeletal muscle releases IL-6 into the blood independent of muscle damage, where acutely it behaves as an anti-inflammatory myokine promoting IL-10 and IL-1 receptor antagonist, in contrast to the same molecule sitting chronically elevated at rest. Repeated training also lowers visceral adiposity, a major source of the chronic inflammatory signal. The average reductions in markers are modest and vary with baseline level, adiposity and the training done, so this is a real but not dramatic lever, and it works alongside its larger effects on fitness and metabolism.
Who this may not transfer to:Pooled mixed-sex trials in middle-aged and older adults; not analyzed as sex-specific here.
The studies · 2
Exercise effects on inflammatory markers in middle-aged and older adults: a network meta-analysis · J Am Med Dir Assoc 2026;27(8):106325
Gleeson et al., The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease · Nat Rev Immunol 2011;11(9):607-615
A Mediterranean diet with olive oil lowers CRP and IL-6 versus a low-fat diet
Eating a Mediterranean-style diet with plenty of olive oil brings inflammation markers down a little compared with a standard low-fat diet. The evidence is on the blood tests, not yet on whether it prevents a specific disease.
This systematic review and meta-analysis of controlled trials compared a Mediterranean diet supplemented with olive oil against a low-fat diet and found reductions in serum inflammatory indexes such as CRP and IL-6 and improvements in endothelial markers. The effects are consistent in direction but modest in size, and the outcomes are circulating biomarkers, not events like heart attacks. This sits within a broader pattern where whole-food dietary patterns move inflammatory markers in a favorable direction; it supports diet quality as a lever on chronic inflammation while stopping short of proving that the marker change is what delivers the diet's known cardiovascular benefit.
Who this may not transfer to:Pooled mixed-sex trials; not reported as sex-specific.
The study · 1
Effect of the Mediterranean diet supplemented with olive oil versus the low-fat diet on serum inflammatory and endothelial indexes: a systematic review and meta-analysis · Nutr Rev 2025;83(7):e1421-e1440
Inflammatory Arthritis
Blocking IL-6 lowers disease activity in rheumatoid arthritis
Rheumatoid arthritis is a case where inflammation is the actual disease, and drugs that block it clearly help. A trial of an IL-6-blocking drug lowered disease activity, and here the CRP number really is measuring the thing being treated.
In autoimmune inflammatory arthritis, inflammatory activity is the pathology, and CRP and ESR are validated measures of disease activity, not distant risk markers. A randomized clinical trial found that tocilizumab, a monoclonal antibody blocking the IL-6 receptor, improved rheumatoid arthritis disease activity both as monotherapy and combined with methotrexate. This is the informative contrast to the rest of the page: where inflammation is measurably driving a defined disease, targeting it directly is standard, effective, evidence-based care, which is exactly why a mildly raised CRP in an otherwise well person is a different situation and not a target to medicate. The trial is one study within a large body of biologic-therapy evidence in rheumatoid arthritis.
Who this may not transfer to:Rheumatoid arthritis cohorts are majority women; the biologic-therapy evidence base is large and mixed-sex.
The lesson is about context, not a treatment suggestion. Blocking inflammation is validated care when inflammation is the diagnosed disease. It does not follow that lowering a mildly elevated CRP in a healthy person with drugs or supplements carries the same benefit.
The study · 1
Tocilizumab monotherapy or combined with methotrexate for rheumatoid arthritis: a randomized clinical trial · JAMA Netw Open 2025;8(5):e2511095
Go Deeper
The pages that act on this biology:
- Muscle as an organ, where a contracting muscle's own anti-inflammatory signaling comes from, and hormesis, the pattern behind why a controlled stress like exercise makes the system more resilient.
- Whole foods, the dietary lever, with resistance training and walking, the movement levers.
- Type 2 diabetes, where inflammation and body fat drive the metabolic disease.
Common Questions
Do anti-inflammatory diets and supplements work?
The label is stuck on almost everything, and most of it rests on petri-dish and rodent experiments, or brief human trials that only move a lab value. Shifting a marker a little is not the same as preventing a heart attack or a diagnosis. Whole-food dietary patterns do lower inflammatory markers modestly. The strongest lever is the plain combination of movement, sleep and body composition.
If inflammation is bad, why not just take an anti-inflammatory drug?
For a healthy person, chronic low-grade inflammation comes from body fat, age and daily habits; a drug that blunts the signal leaves those drivers in place and carries its own risks. Inflammation earns direct drug treatment when it is the disease itself, under a doctor's care.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 13 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.